Terumo Corporation has completed its acquisition of a drug product plant and quality control laboratory operations from WuXi Biologics in Leverkusen, Germany. The transaction officially closed on September 30, 2025.
The acquisition expands Terumo’s position in the contract development and manufacturing organization (CDMO) sector and marks the company’s first European manufacturing base. The move enables the company to meet growing demand for CDMO services, particularly in Europe and the United States, driven by the rapid expansion of the biopharmaceutical market.
State-of-the-Art Leverkusen Facility Capabilities
The newly acquired Leverkusen Drug Product Plant features state-of-the-art facilities compliant with current Good Manufacturing Practice (cGMP) standards and is staffed by highly skilled professionals with deep production know-how. The facility offers:
- Fill & finish services for vials and polymer prefillable syringes
- Complete device assembly capabilities
- Integrated quality control laboratory operations
- Comprehensive end-to-end solution from primary container to fully assembled auto-injectors
- Advanced manufacturing technologies for combination products
“Our expanded footprint in Europe and unique CDMO capabilities will empower biopharmaceutical companies to bring effective treatments for chronic diseases to market more efficiently.”
Noritsugu Fujita, Division President, Pharmaceutical Solutions Division, Terumo
Terumo currently operates three CDMO production facilities in Japan at Kofu, Fujinomiya, and Yamaguchi. The company has expanded production lines at the Yamaguchi factory and is installing new production lines in a newly constructed building at the Kofu factory, scheduled for completion by the end of 2025.
“With our integrated solution – from primary container and fill & finish capabilities to device assembly – customers can bring us their Active Pharmaceutical Ingredient (API) and leave with fully assembled auto-injectors. This is a win-win for both patients and healthcare system, as self-injection systems offer a more cost-effective and patient-friendly way to administer injectable drugs.”
Marco Chiadò Piat, President, Pharmaceutical Solutions, Terumo
Terumo specializes in pharmaceutical primary containers such as prefillable syringes and drug delivery devices using polymer materials. The company operates in the CDMO space for combination products that integrate pharmaceuticals and medical devices. Global expansion of the contract manufacturing business remains a key pillar of Terumo’s future growth strategy.
